The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab

This study looks at how the immune system responds in patients with newly diagnosed glioblastoma (a serious brain tumor) who receive pembrolizumab — an immunotherapy drug — alongside standard treatment including surgery, chemotherapy, and radiation. **You may be eligible if...** - You are between 18 and 70 years old with a new diagnosis of glioblastoma - Your tumor can be surgically removed and is not in a critical brain area - You are physically active and functioning well (Karnofsky score ≥80) - You have not received any prior cancer treatment - Your blood counts, kidney, and liver function are within normal ranges **You may NOT be eligible if...** - You have another active cancer (with some exceptions for low-risk skin cancers) - You have an active autoimmune disease or immunodeficiency - You have had a prior allergic reaction to pembrolizumab or similar drugs - You are pregnant or planning to become pregnant - Your BMI is 35 or above Talk to your doctor to see if this trial is right for you.